21 related articles for article (PubMed ID: 10425301)
1. Combination versus sequential single-agent chemotherapy in the treatment of patients with advanced non-small cell lung cancer.
Niell HB; Griffin JP; Hunter RF; Meredith CA; Somes G
Med Pediatr Oncol; 1989; 17(1):69-75. PubMed ID: 2536462
[TBL] [Abstract][Full Text] [Related]
2. A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer.
Tavakkoli M; Wilkins CR; Mones JV; Mauro MJ
Front Oncol; 2019; 9():295. PubMed ID: 31080780
[TBL] [Abstract][Full Text] [Related]
3. A way forward on the medically appropriate use of white cell growth factors.
Smith TJ; Hillner BE
J Clin Oncol; 2012 May; 30(14):1584-7. PubMed ID: 22370327
[No Abstract] [Full Text] [Related]
4. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
Gridelli C; Perrone F; Palmeri S; D'Aprile M; Cognetti F; Rossi A; Gebbia V; Pepe R; Veltri E; Airoma G; Russo A; Incoronato P; Scinto AF; Palazzolo G; Natali M; Leonardi V; Gallo C; De Placido S; Bianco AR
Ann Oncol; 1996 Oct; 7(8):821-6. PubMed ID: 8922196
[TBL] [Abstract][Full Text] [Related]
5. A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer.
Masutani M; Akusawa H; Kadota A; Ohchi Y; Takahashi N; Tanigawa S; Koya Y; Horie T
Respirology; 1996 Mar; 1(1):49-54. PubMed ID: 9432405
[TBL] [Abstract][Full Text] [Related]
6. The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.
Takada M; Fukuoka M; Ariyoshi Y; Furuse K; Niitani H; Ota K; Motomiya M; Hasegawa K; Tominaga K; Kuriyama T
Cancer Chemother Pharmacol; 1992; 31(3):182-6. PubMed ID: 1281446
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with cisplatin, vindesine and mitomycin-C for advanced, inoperable non-small-cell lung cancer.
Stockler M; Raghavan D; McCaughan BC; Grygiel J; McNeil E; Gianoutsos P; Lee JH
Med J Aust; 1992 May; 156(10):698-700. PubMed ID: 1377770
[TBL] [Abstract][Full Text] [Related]
8. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
Masutani M; Ochi Y; Kadota A; Akusawa H; Kisohara A; Takahashi N; Koya Y; Horie T
Oncol Rep; 2000; 7(2):305-10. PubMed ID: 10671676
[TBL] [Abstract][Full Text] [Related]
9. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
Masuda N
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
[TBL] [Abstract][Full Text] [Related]
10. [Dose intensity chemotherapy in lung cancer].
Takada M; Fukuoka M; Negoro S; Masuda N; Kudo S
Gan To Kagaku Ryoho; 1990 Oct; 17(10):2005-12. PubMed ID: 1699498
[TBL] [Abstract][Full Text] [Related]
11. Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomized trial, can it improve survival of patients with good performance status?
Masutani M; Tsujino I; Fujie T; Yamaguchi M; Miyagi K; Yano T; Takahashi N; Koya Y; Horie T
Oncol Rep; 1999; 6(5):1045-50. PubMed ID: 10425301
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
